Follow last change Jun 2024 re-read 3 minutes ago

BCG

Developed for: bacterial infectious disease with sepsis · diarrheal disease · respiratory tract infectious disorder
Investigated by: Makerere University · Radboud University Medical Center · University of Bergen

today NCT02606526 · Ph 3

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT02606526	Jul 2016 → Jun 2024	bacterial infectious disease with sepsis, diarrheal disease, respiratory tract infectious disorder	Makerere University	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	BCG	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02606526 ↗
Modality	Vaccine	“BCG vaccine” NCT02606526 ↗